## **Creating a Translational Medicine Ontology**



Christine Denney<sup>1</sup>, Colin Batchelor<sup>2</sup>, Olivier Bodenreider<sup>3</sup>, Sam Cheng<sup>4</sup>, John Hart<sup>4</sup>, John Hill<sup>4</sup>, John Madden<sup>5</sup>, Mark Musen<sup>6</sup>, Elgar Pichler<sup>7</sup>, Matthias Samwald<sup>8,9</sup>, Sándor Szalma<sup>10</sup>, Lynn Schriml<sup>11</sup>, David Sedlock<sup>12</sup>, Larisa Soldatova<sup>13</sup>, Koji Sonoda<sup>14</sup>, David Statham<sup>12</sup>, Holger Stenzhorn<sup>8,15</sup>, Patricia L. Whetzel<sup>6</sup>, Elizabeth Wu<sup>16</sup>, Susie Stephens<sup>1</sup>

<sup>1</sup>Eli Lilly, Indianapolis, IN, USA; <sup>2</sup>Royal Society of Chemistry, Cambridge, UK; <sup>3</sup>National Library of Medicine, Bethesda, MD, USA; <sup>4</sup>Boehringer Ingelheim, Ridgefield, CT, USA; <sup>5</sup>Duke University, Durham, NC, USA; <sup>6</sup>Stanford University, Stanford, CA, USA; <sup>7</sup>AstraZeneca, Waltham, MA, USA; <sup>9</sup>DERI, Gallway, Ireland; <sup>9</sup>KLI, Altenberg, Austria; <sup>10</sup>Centocor R&D, San Diego, CA, USA; <sup>11</sup>University of Maryland, Baltimore, MD, USA; <sup>12</sup>Minennium Pharmaceuticals, Cambridge, MA, USA; <sup>13</sup>University of Aberystwyth, Aberystwyth, UK; <sup>14</sup>Minersity Medical Center Freiburg, Germany; <sup>16</sup>Likheimer's Research Forum, Cambridge, MA, USA

